MycoBiomDB – Record Details (MyCo_3130)

Biomarker Record Details

Database ID: MyCo_3130
DB IDMyCo_3130
TitleCombined use of serum (1,3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units
Year2017
PMID28693606
Fungal Diseases involvedCandidemia
Associated Medical ConditionICU Patients
GenusCandida
Speciesglabrata
OrganismCandida glabrata
Ethical StatementSpecific informed consent for this study was not necessary because of the retrospective nature of the analyses. The study was approved by the Ethics Committee of the coordinating centre (Regional Ethics Committee of Liguria Region, N. Registro CER Liguria: 270REG2016).
Site of InfectionNone
Opportunistic invasiveNone
Sample typeBody fluid
Sample sourceSerum
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker NamePCT + BDG
Biomarker Full NameProcalcitonin + 1-3-beta-D-Glucan
Biomarker TypeDiagnostic
BiomoleculeProtein
Geographical LocationItaly
CohortFrom June 2014 to December 2015, all adult patients admitted to the ICU who had a culture-proven candidaemia or bacteraemia, as well as BDG and PCT measured closely to the time of the index culture, were included in the study. One hundred and sixty-six patients were included, 73 with candidaemia (44%) and 93 with bacteraemia (56%).
Cohort No.166
Age Group52-76
P ValueNone
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismNone
TechniqueELISA + Immunological assay
Analysis MethodFDA approved Fungitell assay+sandwich chemiluminescence immunoassay
ELISA kitssandwich chemiluminescence immunoassay (CLIA; Li- aison® BRAHMS® PCT II GEN, DiaSorin, Saluggia, Italy)
Assay DataFDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA
Validation Techniques usedFDA approved Fungitell assay+sandwich chemiluminescence immunoassay
Up Regulation Down RegulationPositive
Sequence DataNone
External LinkNone